# Vyjuvek (beremagene geperpavec) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/beremagene-geperpavec

> The FDA approved Vyjuvek (beremagene geperpavec), sponsored by Krystal Biotech, Inc. (KRYS), on May 2023 for dystrophic epidermolysis bullosa.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Vyjuvek (beremagene geperpavec) FDA approved?

Yes. The FDA approved Vyjuvek (beremagene geperpavec), sponsored by Krystal Biotech, Inc. (KRYS), on May 2023 for dystrophic epidermolysis bullosa. SEC Form 10-Q: "•our commercialization plans in the United States, the European Union ("EU"), Japan, and elsewhere for our first commercial product, VYJUVEK® (beremagene geperpavec-svdt), which was approved by the U.S. Food and Drug Administration ("FDA") in May 2023, the European Commission ("EC") in April 2025, and Japan's Ministry of Health, Labour and Welfare ("MHLW") in July 2025 for the treatment of dystrophic epidermolysis bullosa ("DEB");" [Calendar and source filings](https://sec-api.dev/pdufa/beremagene-geperpavec)

Source: SEC Form 10-Q, accession 0001711279-25-000087, https://www.sec.gov/Archives/edgar/data/1711279/000171127925000087/krys-20250930.htm (retrieved 2026-11-12). Last confirmed 2025-11-03. Cite: https://sec-api.dev/pdufa/beremagene-geperpavec#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Vyjuvek (beremagene geperpavec) |
| Codes |  |
| Sponsor | Krystal Biotech, Inc. (KRYS) https://sec-api.dev/companies/krys/catalysts |
| Indications | dystrophic epidermolysis bullosa |
| Modality | gene_therapy |
| FDA designations | none disclosed |

## Timeline

### May 2023: FDA approval

- Status: completed, approved. Date confidence: month. Indication: dystrophic epidermolysis bullosa.
- First seen 2025-04-28, last confirmed 2025-11-03.
- SEC Form 10-Q (accession 0001711279-25-000087): "•our commercialization plans in the United States, the European Union ("EU"), Japan, and elsewhere for our first commercial product, VYJUVEK® (beremagene geperpavec-svdt), which was approved by the U.S. Food and Drug Administration ("FDA") in May 2023, the European Commission ("EC") in April 2025, and Japan's Ministry of Health, Labour and Welfare ("MHLW") in July 2025 for the treatment of dystrophic epidermolysis bullosa ("DEB");" https://www.sec.gov/Archives/edgar/data/1711279/000171127925000087/krys-20250930.htm
- SEC Form 10-Q (accession 0001711279-25-000077): "•our commercialization plans in the United States, the European Union ("EU"), and Japan for our first commercial product, VYJUVEK® (beremagene geperpavec-svdt), which was approved by the U.S. Food and Drug Administration ("FDA") in May 2023, the European Commission ("EC") in April 2025, and Japan's Ministry of Health, Labour and Welfare ("MHLW") in July 2025 for the treatment of dystrophic epidermolysis bullosa ("DEB");" https://www.sec.gov/Archives/edgar/data/1711279/000171127925000077/krys-20250630.htm
- SEC Form 10-Q (accession 0001711279-25-000044): "•our commercialization plans in the United States and the European Union ("EU") for our first commercial product, VYJUVEK® (beremagene geperpavec-svdt), which was approved by the U.S. Food and Drug Administration ("FDA") in May 2023 and the European Medicines Agency ("EMA") in April 2025 for the treatment of dystrophic epidermolysis bullosa ("DEB");" https://www.sec.gov/Archives/edgar/data/1711279/000171127925000044/krys-20250331.htm
- Press release filed with the SEC (EX-99) (accession 0001711279-25-000029): "VYJUVEK was approved by the FDA in the United States in May 2023 and is also under review for approval by Japan's Pharmaceuticals and Medical Devices Agency with a decision expected in 2H 2025." https://www.sec.gov/Archives/edgar/data/1711279/000171127925000029/a042025-exhibit991.htm

### January 11, 2026: earnings report

- Status: completed. Date confidence: exact.
- First seen 2026-01-12, last confirmed 2026-01-12.
- Press release filed with the SEC (EX-99) (accession 0001711279-26-000008): "PITTSBURGH, January 11, 2026 (GLOBE NEWSWIRE) - Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS) today announced selected preliminary unaudited 2025 financial results, including fourth quarter and full year 2025 VYJUVEK® net product revenue, and outlined the Company's strategic vision to drive the next stage of growth of its rare disease business." https://www.sec.gov/Archives/edgar/data/1711279/000171127926000008/jpm2026preannouncementprex.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/beremagene-geperpavec.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Vyjuvek (beremagene geperpavec) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/beremagene-geperpavec

```bibtex
@misc{secapidev_pdufa_beremagene_geperpavec_20261116,
  title        = {Vyjuvek (beremagene geperpavec) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/beremagene-geperpavec}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_beremagene_geperpavec_20261116","title":"Vyjuvek (beremagene geperpavec) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/beremagene-geperpavec","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
